Skip to main content

Table 1 Demographics of clinical samples

From: Combined genetic mutations and DNA-methylated genes as biomarkers for endometrial cancer detection from cervical scrapings

Variables

Normal endometrium

Benign diseases

Hyperplasia

Endometrial cancer (EC)

Type I

Type II

Number of cases

12

20

18

30

16

Age (years)

53.4 ± 5.6

46.2 ± 5.8

46.4 ± 6.5

55.3 ± 6.9

59.6 ± 8.7

Subtypes

 Adenomyosis

 

1 (5%)

   

 Leiomyoma

 

10 (50%)

   

 Adenomyosis and leiomyoma

 

9 (45%)

   

 Endometrial hyperplasia

  

12 (42.9%)

  

 Atypical endometrial hyperplasia

  

6 (33.3%)

  

Histotypes of cancer

 Endometrioid

   

30 (100%)

3 (18.8%)

 Serous

   

0

6 (37.5%)

 Others

   

0

7 (43.8%)

FIGO stage of cancer

 I

   

28 (93.3%)

10 (62.5%)

 II

   

0

1 (6.2%)

 III

   

1 (3.3%)

3 (18.8%)

 IV

   

1 (3.3%)

2 (12.5%)

Histological grade of cancer

 G1

   

20 (66.7%)

4 (25.0%)

 G2

   

8 (26.7%)

2 (12.5%)

 G3

   

0

9 (56.2%)

 Unknown

   

2 (6.7%)

1 (6.2%)